Patients

For patients, management of a rare disease can be all-consuming. At MBX Biosciences, we are dedicated to making meaningful improvements in patients’ lives by minimizing their daily burden.

Canvuparatide (MBX 2109) is currently in a pivotal Phase 3 clinical trial (NCT07699471), paving the way towards a new approach for patients and physicians alike.

Through our innovative research, discovery, and development of novel therapeutics, we aim to change the therapeutic landscape for those living with hypoparathyroidism, obesity and other rare or prevalent diseases.

Patient Stories

Resources & Advocacy

Current Clinical Trials

The Phase 3 oPTimize™ trial is a multicenter, randomized, double-blind, placebo controlled study evaluating the efficacy and safety of once-weekly canvuparatide in adults with chronic hypoparathyroidism, followed by a 78-week open-label extension. Canvuparatide will be administered once weekly. Learn more here.

Our lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent PEP™ GLP-1/GIP co-agonist prodrug with the goal of potential once-monthly dosing frequency and improved efficacy and tolerability relative to existing standards of care. MBX 4291 is currently in Phase 1 clinical evaluation, focusing on safety, tolerability, and pharmacokinetics in adult participants with obesity. More information in the Phase 1 trial design can be found here.

We are continually working with patients and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond.

For questions or interest in participating in our clinical trials, please email us.

Info@mbxbio.com